OpenLegislation

Article 3 Content of the Annex to the pharmacovigilance system master fileF1

United Kingdom

Original text. Later amendments are not shown.

The pharmacovigilance system master file shall have an Annex containing the following documents:

  1. (1)

    a list of medicinal products covered by the pharmacovigilance system master file, including the name of the medicinal product, the international non-proprietary name (INN) of the active substance(s), and the Member State(s) in which the authorisation is valid;

  2. (2)

    a list of written policies and procedures for the purpose of complying with Article 11(1);

  3. (3)

    the list of subcontracts referred to in Article 6(2);

  4. (4)

    a list of the tasks that have been delegated by the qualified person for pharmacovigilance;

  5. (5)

    a list of all scheduled and completed audits;

  6. (6)

    where applicable, a list of the performance indicators referred to in Article 9;

  7. (7)

    where applicable, a list of other pharmacovigilance system master files held by the same marketing authorisation holder;

  8. (8)

    a logbook containing the information referred to in Article 5(4).

Annotations

Textual amendments

F1

Regulation revoked in part (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 9 para. 1(t) (subject to transitional provisions in S.I. 2012/1916, Sch. 33A); 2020 c. 1, Sch. 5 para. 1(1)